News >

Immunotherapy Combos May Mark Future of Gastric Cancer Care

Brandon Scalea
Published: Wednesday, Mar 20, 2019

Rutika Mehta, MD, MPH

Rutika Mehta, MD, MPH

More agents continue to enter the treatment armamentarium for patients with gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma, with the future bringing immunotherapy combinations to the forefront of treatment, said Rutika Mehta, MD, MPH.

In results presented at the 2019 Gastrointestinal Cancers Symposium, investigators reported that the combination of pembrolizumab (Keytruda), trastuzumab (Herceptin), and chemotherapy was found to have high activity in patients with untreated metastatic HER2-positive esophagogastric adenocarcinoma in a small clinical trial. Specifically, among 35 evaluable patients, 67% remained free of disease progression at 6 months with the combination.1

“The near future will bring more immunotherapy-based combinations to the forefront,” said Mehta, a gastrointestinal medical oncologist at Moffitt Cancer Center.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication